Effect of oral CDP-choline on visual function in young amblyopic patients

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 1, 2008, Pages 143-150

  Fresina, Michela ^a   Dickmann, Anna ^b   Salerni, Annabella ^b   De Gregorio, Fabio ^c   Campos, Emilio C ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c R and D   (Italy)

Author keywords

Amblyopia; CDP choline; Citicoline; Medical treatment; Visual acuity

Indexed keywords

CEBROLUX; CITICOLINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AMBLYOPIA; ANALYSIS OF VARIANCE; ANISOMETROPIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTRAST SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE PROTECTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STRABISMUS; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADMINISTRATION, ORAL; AMBLYOPIA; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYTIDINE DIPHOSPHATE CHOLINE; FEMALE; HUMANS; MALE; SENSORY DEPRIVATION; VISUAL ACUITY;

EID: 36448944696     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-007-0621-6     Document Type: Article

References (47)

1. Snowdon SK, Stewart-Brown SL (1997) Preschool vision screening. Health Technol Assess 1:1-85
2. Newman DK, East MM (2000) Prevalence of amblyopia among defaulters of preschool vision screening. Ophthalmic Epidemiol 7(1):67-71
3. Adams DL (2005) Normal and abnormal visual development. In: Taylor D, Hoyt CS (eds) Pediatric ophthalmology and strabismus. Elsevier Saunders, Edinburgh, pp 9-22
4. Repka MX (2005) Amblyopia management. In: Taylor D, Hoyt CS (eds) Pediatric ophthalmology and strabismus. Elsevier Saunders, Edinburgh, pp 862-868
5. Secades JJ (2001) CDP-choline update and review of its pharmacology and clinical use. Methods Find Exp Clin Pharmacol 23 [Suppl B]:1-53
6. Secades J, Frontera G (1995) CDP-choline: Pharmacological and clinical review. Methods Find Exp Clin Pharmacol 17 [Suppl B]:1-54
7. Agnoli A, Ruggieri S, Denaro A, Bruno G (1982) New strategies in the management of Parkinson's disease. A biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology 8:289-296
8. Eberhardt R, Birbamer G, Gerstenbrand F, Rainer E, Traegner H (1990) Citicoline in the treatment of Parkinson's disease. Clin Ther 12:489-495
9. Davalos A, Castillo J, Alvarez-Sabin JA et al (2002) Oral citicoline in acute ischemic stroke. An individual patient data pooling analysis of clinical trials. Stroke 33:2850-2857
10. Martinez-Villa E, Sieria PI (2001) Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 11 [Suppl 1]:60-70
11. Pecori Giraldi J, Virno M, Covelli G, Grechi G, De Gregorio F (1989) Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). Int Ophthalmol 13:109-112
12. Covelli GP, De Gregorio F, Grechi G, Pecori Giraldi J (1989) Efficacia della citicolina nei difetti perimetrici a settore. Boll Ocul 68 [Suppl 4]:353-361
13. Virno M, Pecori Giraldi J, Liguori A, De Gregorio F (2000) The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol Scand 78 [Suppl]:56-57
14. Brogliatti B, Rolle T, Cantatore A, Bianco M (1991) Citicolina versus gangliosidi versus GM1: Effetti sulla sensibilità retinica centrale in pazienti glaucomatosi. Boll Ocul 70 [Suppl 2]:1-8
15. Parisi V, Manni G, Colacino G, Bucci MG (1999) Cytidine-5′-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 106(6):1126-1134
16. McMurray WC, Magee WI (1972) Phospholipid metabolism. Ann Rev Biochem 41:129-161
17. Farooqui AA, Horrocks LA, Farooqui T (2000) Glycerophospholipids in brain: Their metabolism incorporation to membranes, function, and involvement in neurological disorders. Chem Phys Lipids 106:1-29
18. Cohadon F, Rigoulet M, Guerin B, Vendendriessche M (1979) Edeme cerebral vasogenique. Alterations des ATPases membranaires. Restauration par un precurseur des phospholipides. Nouv Presse Med 8:1589-1591
19. Goto Y, Okamoto S, Yonekawa Y et al (1988) Degradation of phospholipid molecular species during experimental cerebral ischemia in rats. Stroke 19:728-735
20. Hirashima Y, Moto A, Endo S, Takaku A (1989) Activities of enzymes metabolizing phospholipids in rat cerebral ischemia. Mol Chem Neuropathol 10:87-100
21. Cohen MM (1973) Biochemistry of cerebral anoxia, hypoxia and ischemia. Monogr Neural Sci 1:1-49
22. Mykita S, Golly F, Dreyfus H, Freysz L, Massarelli R (1986) Effect of CDP-choline on hypocapnic neurons in culture. J Neurochem 47:223-231
23. Schäbitz WR, Weber J, Takano K, Sandage BW, Locke KW, Fisher M (1996) The effect of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci 183:21-25
24. Bladergroen BA, Bussiere M, Klein W et al (1999) Inhibition of phosphatidylcholine and phosphatidylethanolamine biosynthesis in rat-2 fibroblasts by cell-permeable ceramides. Eur J Biochem 264:152-160
25. Rao AM, Hatcher JF, Dempsey RJ (2001) Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Res 893:268-272
26. Onal MZ, Tatlisumak T, Locke KW, Sandage BW, Fisher M (1997) Synergistic effect of citicoline and MK-801 in temporary experimental focal ischemia in rats. Stroke 28:1060-1065
27. Agut J, Coviella IL, Wurtman RJ (1984) Cytidine(5′)diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine. Neuropharmacology 23:1403-1406
28. Witkovsky P, Dearry A (1991) Functional roles of dopamine in the vertebrate retina. Prog Retin Res 11:247-292
29. Simon A, Nguyen-Legros J (1995) Are there dopaminergic ganglion cells in the mammalian retina? Neurochem Int 27:279-283
30. Nguyen-Legros J, Harnois C, DiPaolo T, Simon A (1993) The retinal dopamine system in Parkinson's disease. Clin Vis Sci 8:1-12
31. Gottlob I, Schneider E, Heider W, Skrandies W (1987) Alteration of visual evoked potentials and electroretinograms in Parkinson's disease. Electroencephalogr Clin Neurophysiol 66:349-357
32. Antal A, Bandini F, Keri S, Bodis-Wollner I (1998) Visuo-cognitive dysfunctions in Parkinson's disease. Clin Neurosci 5:147-152
33. Rejdak R, Toczoowski J, Solski J, Duma D, Grieb P (2002) Citicoline treatment increases retinal dopamine content in rabbits. Ophthalmic Res 34:146-149
34. Gottlob I, Charlier J, Reinecke RD (1992) Visual acuities and scotomas after one week levodopa administration in human amblyopia. Invest Ophthalmol Vis Sci 33(9):2722-2728
35. Leguire LE, Rogers GL, Wilson PD et al (1998) Occlusion and levodopa-carbidopa treatment for childhood amblyopia. J AAPOS 2:257-264
36. Campos EC, Bolzani R, Schiavi C, Baldi A, Porciatti V (1997) Cytidin-5′-diphosphocholine enhances the effect of part-time occlusion in amblyopia. Doc Ophthalmol 93:247-263
37. Campos EC, Schiavi C, Benedetti P, Bolzani R, Porciatti V (1995) Effect of citicoline on visual acuity in amblyopia: Preliminary results. Graefes Arch Clin Exp Ophthalmol 233:307-312
38. Campos EC (1997) Future direction in the treatment of amblyopia. Lancet 349:1190
39. Porciatti V, Schiavi C, Benedetti P, Baldi A, Campos EC (1998) Cytidine-5′-diphosphocholine improves visual acuity, contrast sensitivity and visual-evoked potentials of amblyopic subjects. Curr Eye Res 17:141-148
40. Becker R, Graf M (2006) Landolt C and Snellen E acuity: Differences in strabismus amblyopia? Klin Monatsbl Augenheilkd 223:24-28
41. Galletti P, De Rosa M, Nappi MA, Pontoni G, Del Piano L, Salluzzo A, Zappia V (1985) Transport and metabolism of double-labelled CDP-choline in mammalian tissues. Biochem Pharmacol 34:4121-4130
42. Lopez-Coviella I, Agut J, Savci V, Ortiz JA, Wurtman RJ (1995) Evidence that 5′-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma level. J Neurochem 65:889-894
43. 14C CDP-choline by oral route. Arzneimittelforschung 33(II):1045-1047
44. Lopez-Coviella I, Agut J, Von Borstel R, Wurtman RJ (1987) Metabolism of cytidine (5′)-diphosphocholine (CDP-choline) following oral and intravenous administration to the human and the rat. Neurochem Int 11:293-297
45. Grau T, Romero A, Sacristan A, Ortiz JA (1983) CDP-choline: Acute toxicity study. Arzneimittelforschung 33(II):1033-1034
46. Grau T, Romero A, Sacristan A, Ortiz JA (1983) Study of subacute toxicity of CDP-choline after 30 days of oral administration. Arzneimittelforschung 33(II):1035-1038
47. Grau T, Romero A, Sacristan A, Ortiz JA (1983) CDP-choline: 6-month study toxicity on dogs. Arzneimittelforschung 33(II):1038-1042